

Appendix: Tables

1.	Sales January to June 2021 and 2020	2
2.	Quarterly sales and constant exchange rate sales growth by Division in 2021 and 2020.....	3
3.	Pharmaceuticals Division – Top-selling pharmaceuticals sales and constant exchange rate growth HY 2021 vs. HY 2020.....	4
4.	Pharmaceuticals Division – New products sales and constant exchange rate growth HY 2021 vs. HY 2020	5
5.	Top 20 Pharmaceuticals Division product sales and constant exchange rate growth HY 2021 vs. HY 2020.....	6
6.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth	7
7.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States.....	8
8.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe.....	9
9.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan	10
10.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International	11
11.	Roche Group consolidated income statement for the six months ended 30 June 2021.....	12
12.	Roche Group core results reconciliation – Half Year 2021	13
13.	Divisional core results reconciliation – Half Year 2021.....	14
14.	Roche Group consolidated balance sheet	15
15.	Roche Group consolidated statement of cash flows	16

1. Sales January to June 2021 and 2020

CHF millions	Six months ended 30 June		% change	
	2021	2020	At CER	In CHF
Pharmaceuticals Division	21,671	23,202	-3	-7
United States	10,802	12,464	-8	-13
Europe	4,485	4,190	4	7
Japan	1,808	1,908	0	-5
International*	4,576	4,640	2	-1
Diagnostics Division	9,042	6,079	51	49
Roche Group	30,713	29,281	8	5

* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

2. Quarterly sales and constant exchange rate sales growth by Division in 2021 and 2020

CHF millions	Q2 2020	% change vs. Q2 2019	Q3 2020	% change vs. Q3 2019	Q4 2020	% change vs. Q4 2019	Q1 2021	% change vs. Q1 2020	Q2 2021	% change vs. Q2 2020
Pharmaceuticals Division	10,940	-6	11,115	-4	10,215	-7	10,600	-9	11,071	4
United States	5,848	-10	5,925	-5	5,258	-13	5,292	-14	5,510	0
Europe	1,926	-3	2,078	2	1,930	-8	2,175	-6	2,310	15
Japan	960	-7	894	-13	963	-5	852	-7	956	7
International*	2,206	5	2,218	-2	2,064	11	2,281	0	2,295	4
Diagnostics Division	3,198	2	3,583	18	4,129	28	4,330	55	4,712	48
Roche Group	14,138	-4	14,698	1	14,344	1	14,930	3	15,783	14

*Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

3. Pharmaceuticals Division – Top-selling pharmaceuticals sales and constant exchange rate growth HY 2021 vs. HY 2020

Top-selling pharmaceuticals January - June 2021	Total		United States		Europe		Japan		International*	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Ocrevus	2,438	23	1,849	18	422	38	-	-	167	60
Perjeta	1,968	5	703	-3	578	-1	132	-6	555	28
Avastin	1,645	-40	530	-47	257	-69	330	-4	528	-12
Actemra/RoActemra	1,642	17	689	6	456	16	182	6	315	63
Tecentriq	1,599	29	811	16	339	17	257	84	192	68
Herceptin	1,396	-35	348	-56	277	-25	43	-40	728	-19
Hemlibra	1,393	45	837	34	292	95	166	16	98	138
MabThera/Rituxan	1,379	-41	855	-46	134	-35	20	-35	370	-27
Kadcyla	959	19	401	6	336	27	60	56	162	31
Xolair	887	-1	887	-1	-	-	-	-	-	-

* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

4. Pharmaceuticals Division – New products sales and constant exchange rate growth HY 2021 vs. HY 2020

New products January - June 2021	Total		United States		Europe		Japan		International*	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Erivedge	127	-9	81	-13	30	-5	-	-	16	12
Perjeta	1,968	5	703	-3	578	-1	132	-6	555	28
Kadcyla	959	19	401	6	336	27	60	56	162	31
Gazyva/Gazyvaro	324	8	153	13	106	2	31	-9	34	22
Esbriet	526	-3	361	-4	137	-1	-	-	28	-4
Cotellic	24	-6	7	25	9	-25	-	-	8	0
Alecensa	631	20	167	6	148	15	118	9	198	52
Tecentriq	1,599	29	811	16	339	17	257	84	192	68
Ocrevus	2,438	23	1,849	18	422	38	-	-	167	60
Hemlibra	1,393	45	837	34	292	95	166	16	98	138
Xofluza	-8	-	-8	-	-	-	-	-	-	-
Polivy	94	17	40	-24	41	52	8	-	5	**
Rozlytrek	22	182	14	112	3	**	3	367	2	**
Phesgo	96	-	52	-	39	-	-	-	5	-
Enspryng	39	-	8	-	-	-	30	-	1	-
Evrysdi	243	-	166	-	27	-	-	-	50	-
Ronapreve	595	-	-	-	483	-	-	-	112	-

* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

** Over 500%

5. Top 20 Pharmaceuticals Division product sales and constant exchange rate growth HY 2021 vs. HY 2020

CHF millions	Total		United States		Europe		Japan		International*	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Ocrevus	2,438	23	1,849	18	422	38	-	-	167	60
Perjeta	1,968	5	703	-3	578	-1	132	-6	555	28
Avastin	1,645	-40	530	-47	257	-69	330	-4	528	-12
Actemra/RoActemra	1,642	17	689	6	456	16	182	6	315	63
Tecentriq	1,599	29	811	16	339	17	257	84	192	68
Herceptin	1,396	-35	348	-56	277	-25	43	-40	728	-19
Hemlibra	1,393	45	837	34	292	95	166	16	98	138
MabThera/Rituxan	1,379	-41	855	-46	134	-35	20	-35	370	-27
Kadcyla	959	19	401	6	336	27	60	56	162	31
Xolair	887	-1	887	-1	-	-	-	-	-	-
Lucentis	665	-3	665	-3	-	-	-	-	-	-
Alecensa	631	20	167	6	148	15	118	9	198	52
Activase/TNKase	598	-8	570	-9	-	-	-	-	28	-2
Ronapreve	595	-	-	-	483	-	-	-	112	-
Esbriet	526	-3	361	-4	137	-1	-	-	28	-4
Gazyva	324	8	153	13	106	2	31	-9	34	22
CellCept	298	-4	23	-25	77	-6	35	-8	163	1
Pulmozyme	276	-18	173	-25	60	-14	0	-16	43	16
Evrysdi	243	-	166	-	27	-	-	-	50	-
Mircera	214	-12	-	-	27	-15	60	-16	127	-8

* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

6. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth

CHF millions	Q2 2020	% change vs. Q2 2019	Q3 2020	% change vs. Q3 2019	Q4 2020	% change vs. Q4 2019	Q1 2021	% change vs. Q1 2020	Q2 2021	% change vs. Q2 2020
Ocrevus	964	12	1,198	37	1,052	10	1,226	16	1,212	31
Perjeta	930	12	988	17	954	20	988	2	980	7
Avastin	1,338	-24	1,188	-30	969	-35	863	-40	782	-40
Actemra/RoActemra	795	40	673	27	724	29	779	22	863	12
Tecentriq	653	54	718	49	723	35	775	26	824	31
Herceptin	993	-33	879	-38	653	-43	755	-35	641	-35
Hemlibra	482	59	572	57	615	45	661	33	732	58
MabThera/Rituxan	1,051	-32	1,003	-33	780	-43	705	-46	674	-34
Kadcyla	409	26	458	33	450	26	478	17	481	21
Xolair	490	1	493	3	453	3	409	-6	478	3
Lucentis	341	-25	392	-5	324	-22	337	-7	328	2
Alecensa	272	27	301	37	319	54	298	14	333	25
Activase/TNKase	301	-3	314	1	316	11	304	-17	294	3
Ronapreve	-	-	-	-	-	-	166	-	429	-
Esbriet	274	2	278	5	264	-9	256	-8	270	1
Gazyva	145	23	162	15	160	6	155	-2	169	18
CellCept	148	-2	148	-11	144	-1	154	-5	144	-3
Pulmozyme	161	-10	148	-16	142	-17	139	-23	137	-13
Evrysdi	-	-	8	-	47	-	80	-	163	-
Mircera	125	-7	118	-26	101	-24	105	-13	109	-10

8. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe

CHF millions	Q2 2020	% change vs. Q2 2019	Q3 2020	% change vs. Q3 2019	Q4 2020	% change vs. Q4 2019	Q1 2021	% change vs. Q1 2020	Q2 2021	% change vs. Q2 2020
Ocrevus	141	26	193	56	184	20	217	37	205	40
Perjeta	260	1	291	13	292	4	301	-3	277	2
Avastin	373	-13	286	-33	170	-61	138	-68	119	-69
Actemra/RoActemra	173	2	186	10	215	24	239	12	217	20
Tecentriq	137	90	155	72	139	18	168	14	171	20
Herceptin	168	-33	161	-30	143	-31	146	-25	131	-25
Hemlibra	68	92	115	171	112	99	136	71	156	123
MabThera/Rituxan	79	-44	102	-29	75	-36	69	-45	65	-21
Kadcyla	125	26	147	39	156	34	167	24	169	29
Xolair	-	-	-	-	-	-	-	-	-	-
Lucentis	-	-	-	-	-	-	-	-	-	-
Alecensa	59	27	68	22	71	22	74	11	74	19
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Ronapreve	-	-	-	-	-	-	166	-	317	-
Esbriet	60	-3	64	-2	68	2	69	-10	68	9
Gazyva	45	13	54	26	56	15	51	-11	55	19
CellCept	32	-20	39	-8	38	-10	38	-22	39	17
Pulmozyme	31	0	31	3	34	4	30	-20	30	-7
Evrysdi	-	-	-	-	-	-	-	-	27	-
Mircera	14	-13	14	-14	13	-17	13	-23	14	-7

9. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan

CHF millions	Q2 2020	% change vs. Q2 2019	Q3 2020	% change vs. Q3 2019	Q4 2020	% change vs. Q4 2019	Q1 2021	% change vs. Q1 2020	Q2 2021	% change vs. Q2 2020
Ocrevus	-	-	-	-	-	-	-	-	-	-
Perjeta	75	11	70	-9	75	0	64	-11	68	-2
Avastin	182	-19	171	-25	183	-7	161	-8	169	0
Actemra/RoActemra	92	-8	86	-15	99	1	84	-2	98	15
Tecentriq	79	94	77	62	105	75	120	82	137	86
Herceptin	37	-45	32	-46	31	-43	22	-43	21	-37
Hemlibra	77	36	76	13	86	15	79	11	87	21
MabThera/Rituxan	16	-45	15	-38	16	-34	10	-37	10	-34
Kadcyla	23	3	22	7	27	41	27	54	33	57
Xolair	-	-	-	-	-	-	-	-	-	-
Lucentis	-	-	-	-	-	-	-	-	-	-
Alecensa	62	8	58	8	67	29	55	8	63	10
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Ronapreve	-	-	-	-	-	-	-	-	-	-
Esbriet	-	-	-	-	-	-	-	-	-	-
Gazyva	21	65	15	-36	18	-9	14	1	17	-17
CellCept	21	-6	19	-3	21	1	17	-9	18	-7
Pulmozyme	0	12	1	40	0	-15	0	-23	0	-9
Evrysdi	-	-	-	-	-	-	-	-	-	-
Mircera	38	-29	39	-20	40	-18	29	-18	31	-15

10. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International*

CHF millions	Q2 2020	% change vs. Q2 2019	Q3 2020	% change vs. Q3 2019	Q4 2020	% change vs. Q4 2019	Q1 2021	% change vs. Q1 2020	Q2 2021	% change vs. Q2 2020
Ocrevus	50	43	66	74	70	55	95	77	72	41
Perjeta	220	50	259	52	249	135	263	23	292	34
Avastin	312	-6	299	-14	310	8	277	-4	251	-20
Actemra/RoActemra	134	123	151	209	140	114	151	134	164	27
Tecentriq	69	120	64	74	79	86	92	84	100	56
Herceptin	415	-14	373	-28	284	-29	396	-16	332	-22
Hemlibra	26	319	25	58	49	325	48	214	50	92
MabThera/Rituxan	236	-25	214	-30	190	-24	200	-23	170	-30
Kadcyla	61	12	76	30	77	50	84	28	78	35
Xolair	-	-	-	-	-	-	-	-	-	-
Lucentis	-	-	-	-	-	-	-	-	-	-
Alecensa	67	107	86	141	95	**	92	44	106	59
Activase/TNKase	13	4	12	-5	14	1	13	-10	15	6
Ronapreve	-	-	-	-	-	-	-	-	112	-
Esbriet	14	3	14	5	10	-9	14	0	14	-7
Gazyva	14	16	15	5	15	-1	16	21	18	23
CellCept	81	18	75	-10	70	4	88	11	75	-8
Pulmozyme	14	-25	17	-6	14	-7	24	3	19	40
Evrysdi	-	-	-	-	1	-	1	-	49	-
Mircera	73	13	65	-31	48	-30	63	-8	64	-8

* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

** Over 500%

11. Roche Group consolidated income statement for the six months ended 30 June 2021

in millions of CHF	Pharma- ceuticals	Diagnostics	Corporate	Group
Sales	21,671	9,042	-	30,713
Royalties and other operating income	1,372	48	-	1,420
Cost of sales	(4,515)	(4,477)	-	(8,992)
Marketing and distribution	(3,086)	(1,403)	-	(4,489)
Research and development	(6,280)	(830)	-	(7,110)
General and administration	(849)	(334)	(282)	(1,465)
Operating profit	8,313	2,046	(282)	10,077
Financing costs				(211)
Other financial income (expense)				21
Profit before taxes				9,887
Income taxes				(1,671)
Net income				8,216
Attributable to				
- Roche shareholders				7,803
- Non-controlling interests				413
Earnings per share and non-voting equity security				
Basic (CHF)				9.14
Diluted (CHF)				9.05

12. Roche Group core results reconciliation – Half Year 2021

in millions of CHF	IFRS	Global restructuring	Intangibles amortisation	Intangibles impairment	Mergers and acquisitions and alliance transactions	Legal & environmental	Pension plan settlements	Global issues	Normalisation of ECP tax benefit	Core
Sales	30,713	-	-	-	-	-	-	-	-	30,713
Royalties and other operating income	1,420	-	-	-	-	-	-	-	-	1,420
Cost of sales	(8,992)	88	656	-	11	-	-	-	-	(8,237)
Marketing and distribution	(4,489)	180	17	-	-	-	-	-	-	(4,292)
Research and development	(7,110)	98	157	165	-	-	-	-	-	(6,690)
General and administration	(1,465)	145	-	-	26	32	-	-	-	(1,262)
Operating profit	10,077	511	830	165	37	32	-	-	-	11,652
Financing costs	(211)	-	-	-	2	2	-	-	-	(207)
Other financial income (expense)	21	-	-	-	-	-	-	-	-	21
Profit before taxes	9,887	511	830	165	39	34	-	-	-	11,466
Income taxes	(1,671)	(106)	(114)	(31)	(8)	(7)	-	-	(2)	(1,939)
Net income	8,216	405	716	134	31	27	-	-	(2)	9,527
Attributable to										
- Roche shareholders	7,803	400	711	134	31	27	-	-	(2)	9,104
- Non-controlling interests	413	5	5	-	-	-	-	-	-	423
EPS - diluted (CHF)	9.05	0.47	0.81	0.16	0.04	0.03	-	-	-	10.56

14. Roche Group consolidated balance sheet

in millions of CHF	30 June 2021	31 December 2020	31 December 2019*
Non-current assets			
Property, plant and equipment	23,172	22,158	22,173
Right-of-use assets	1,128	1,112	1,145
Goodwill	10,623	9,249	10,295
Intangible assets	12,510	12,017	10,751
Deferred tax assets	5,766	5,459	4,979
Defined benefit plan assets	1,229	967	945
Other non-current assets	2,199	2,234	1,549
Total non-current assets	56,627	53,196	51,837
Current assets			
Inventories	8,319	7,194	6,055
Accounts receivable	11,656	10,154	10,440
Current income tax assets	153	149	237
Other current assets	3,115	3,111	2,664
Marketable securities	3,017	6,607	5,783
Cash and cash equivalents	5,000	5,727	6,075
Total current assets	31,260	32,942	31,254
Total assets	87,887	86,138	83,091
Non-current liabilities			
Long-term debt	(11,285)	(10,220)	(12,668)
Net deferred tax liabilities	(499)	(353)	(298)
Defined benefit plan liabilities	(6,780)	(7,831)	(7,480)
Provisions	(1,467)	(1,453)	(1,515)
Other non-current liabilities	(1,230)	(1,107)	(1,144)
Total non-current liabilities	(21,261)	(20,964)	(23,105)
Current liabilities			
Short-term debt	(3,726)	(3,996)	(1,695)
Current income tax liabilities	(3,473)	(3,679)	(3,838)
Provisions	(1,940)	(1,836)	(2,885)
Accounts payable	(4,241)	(4,121)	(3,822)
Other current liabilities	(11,813)	(11,769)	(11,879)
Total current liabilities	(25,193)	(25,401)	(24,119)
Total liabilities	(46,454)	(46,365)	(47,224)
Total net assets	41,433	39,773	35,867
Equity			
Capital and reserves attributable to Roche shareholders	37,814	36,341	32,747
Equity attributable to non-controlling interests	3,619	3,432	3,120
Total equity	41,433	39,773	35,867

* The balance sheet at 31 December 2019 has been restated following the finalisation of the valuation of the net assets acquired related to the Spark Therapeutics acquisition in 2019.

15. Roche Group consolidated statement of cash flows

in millions of CHF	HY 2021	HY 2020
Cash flows from operating activities		
Cash generated from operations	13,324	13,807
(Increase) decrease in net working capital	(2,616)	(4,817)
Payments made for defined benefit plans	(288)	(284)
Utilisation of provisions	(511)	(505)
Disposal of products	484	130
Other operating cash flows	2	-
Cash flows from operating activities, before income taxes paid	10,395	8,331
Income taxes paid	(2,183)	(1,269)
Total cash flows from operating activities	8,212	7,062
Cash flows from investing activities		
Purchase of property, plant and equipment	(1,759)	(1,614)
Purchase of intangible assets	(335)	(1,524)
Disposal of property, plant and equipment	38	34
Disposal of intangible assets	-	-
Business combinations	(1,822)	(674)
Divestment of subsidiaries	-	-
Interest and dividends received	1	11
Sales of marketable securities	129	206
Purchases of marketable securities	(99)	(111)
Sales (purchases) of money market instruments and time accounts over three months, net	3,633	3,170
Other investing cash flows	258	(294)
Total cash flows from investing activities	44	(796)
Cash flows from financing activities		
Proceeds from issue of bonds and notes	1,391	-
Redemption and repurchase of bonds and notes	(1,266)	-
Increase (decrease) in commercial paper	191	521
Increase (decrease) in other debt	(19)	393
Hedging and collateral arrangements	(324)	196
Changes in ownership interests in subsidiaries	-	-
Changes in non-controlling interests	-	-
Equity contribution by non-controlling interests - capital injection	-	-
Interest paid	(243)	(264)
Principal portion of lease liabilities paid	(187)	(183)
Dividends paid	(7,955)	(7,806)
Equity-settled equity compensation plans, net of transactions in own equity	(644)	(1,380)
Other financing cash flows	-	3
Total cash flows from financing activities	(9,056)	(8,520)
Net effect of currency translation on cash and cash equivalents	73	(51)
Increase (decrease) in cash and cash equivalents	(727)	(2,305)
Cash and cash equivalents at beginning of period	5,727	6,075
Cash and cash equivalents at end of period	5,000	3,770